Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Debate

Set Alert for Pricing Debate

Pricing In ‘Exceptional’ Times: ICER Aims To Shape US Policy For Novel COVID Drugs, Vaccines

US Institute for Clinical and Economic Review lays out options ranging from the status quo (unrestricted pricing) to compulsory licensing and advanced market commitments in a new white paper.

Pricing Strategies Coronavirus COVID-19 Health Technology Assessment

Latest From Pricing Debate

The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform

Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.

Pricing Debate Rare Diseases

Expectations Are High For New EMA Boss

Emer Cooke seems set to take over as head of the European Medicines Agency – one of the world's most powerful regulatory bodies – before the end of the year. We report on the reaction of a range of pharmaceutical sector stakeholders to her nomination.

Europe Leadership

Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry

Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.

Coronavirus COVID-19 Pricing Debate

NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal

An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.

Europe United Kingdom

Minnesota's Free Insulin Law Has 'Staggering' Implications, PhRMA Says

PhRMA sues to block implementation of the law, saying it could allow states to compel manufacturers to dispense other medications without compensation.

Legal Issues Pricing Debate

Stockwatch: Age And Outcome Duration Cloud Innovative Therapy Reimbursement

Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.

Gene Therapy Reimbursement

English Funding Setback For Novartis’s Mayzent

Novartis says that while the comparators used in the evidence it submitted to NICE were the right ones, it will work to address the health technology assessment body’s outstanding data requirements to secure access to its treatment for secondary progressive multiple sclerosis.

Health Technology Assessment Neurology

Gene Therapies Will Be A Bigger Cost Issue In 2021, PwC Predicts

The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021. 

Gene Therapy Rare Diseases

CMS Changes The Dictionary: Medicaid ‘Best Price’ Could Soon Mean Many Things

Value and outcomes-based purchasing agreements could see a boost under proposed Medicaid rule that CMS says will make it easier for manufacturers to experiment different contracting structures in the commercial health insurance market. CMS says the intent of these agreements is to lower drug prices for commercial payers, but the government acknowledges this is not guaranteed, and health policy experts worry both private payers and Medicaid could end up paying higher prices if the proposal is finalized.

Medicaid Reimbursement
See All